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 ABSTRACT 
 
Background: Patients with blood clotting disorders have severely depleted levels of 
blood clotting factor (BCF) proteins in their blood, which results in a significantly higher 
risk of bleeding events than a typically healthy patient. Serotonin based antidepressant 
medications, such as selective serotonin reuptake inhibitors (SSRI) or serotonin 
norepinephrine reuptake inhibitors (SNRI) alter the levels of serotonin in the blood as a 
mechanism to treat depression.  
Serotonin is used for many different chemical processes within the body including blood 
aggregation. We sought to quantify the potential risk associated with the use of these 
types of antidepressant medications to patients with blood clotting disorders.  
 
Objective: To determine if patients with BCF disorders who are prescribed SSRI or 
SNRI medications are at an increased risk of having a major bleeding event.  
 
Methods: A retrospective cohort study was conducted using data from the Optum 
Clinformatics Data Mart. An initial cohort of 16,124 patients with blood clotting 
disorders was formed; patients were excluded based upon enrollment eligibility, drug 
prescription date outside the study timeframe, and age under 12 years. A final study 
sample of 7,998 patients was formed. A follow up period of six months was selected to 
analyze major bleeding events; these events were identified using ICD-9 codes for 
hemorrhages. Patients were classified as to whether a bleeding event occurred during the 
period. The use of antidepressant medications was determined by prescription drug 
 dispensings three months prior to the follow up period. Both univariate and multivariate 
logistic regression models were built to enhance a final multivariate predictive model.  
Results: The use of SSRI and SNRI antidepressant medications was not associated with 
an increased risk of bleeding events (p=0.93). Risk factors for having a major bleeding 
event included older age (P=<0.0001), male gender (P=<0.0001), diabetes (P=0.0001), 
nonsteroidal anti-inflammatory drug (NSAID) use (p=0.0040), anticoagulant use 
(P=<0.0001), and Hemophilia A (p=0.0001). Patients who were between 46-65 years old 
were 1.85 times more likely to have a major bleeding event than those between the ages 
of 26-45 (95% CI: 1.31-2.61). This risk increases to 3.47 times for those between the 
ages of 66-90 (95% CI: 2.36-5.11). Males were 1.84 times more likely to have a major 
bleeding event in comparison to females (95% CI: 1.42-2.38). Patients who had diabetes 
are at 1.84 times the risk of a major bleeding event than those with diabetes (95% CI: 
1.35-2.52). Patients with Hemophilia A had approximately twice the risk of experiencing 
a bleeding event as compared with patients having other blood clotting disorders (OR 
2.13; 95% CI: 1.54-2.93).  
Conclusion: SSRI and SNRI antidepressant medications were not associated with an 
increased risk of bleeding events in this study. Factors associated with major bleeding 
events included male gender, older age, the use of NSAIDs or anticoagulants, and a 
diagnosis of Hemophilia A. 
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CHAPTER 1 
 
INTRODUCTION 
Blood Clotting Factor disorders (BCF) are defined as inherited disorders that affect the 
body’s ability to clot blood, thus increasing the frequency and duration of bleeding 
events. There are 12 different BCF proteins within the human body responsible for blood 
coagulation. (1) The most common types of BCF disorders are Hemophilia A, 
Hemophilia B, and Von Willebrand disorder. Hemophilia is an extremely rare disease; 
there are an estimated 20,000 cases in the U.S. (2) Hemophilia is a life-long disease that 
is typically diagnosed at an extremely young age either by blood test or by the occurrence 
of a bleeding event. Von Willebrand disease (VWD) is the most common BCF disorder 
that affects approximately 1% of the population. (3) VWD is a genetically inherited 
deficiency in the clotting protein which binds BCF VIII to the vessel walls. VWD occurs 
equally in both men and women; hemophilia occurs almost solely in the male population. 
(2, 3) This is due to hemophilia being an X-linked chromosome disease. The male 
chromosome consists of both an X and a Y chromosome while the female chromosome 
has two X. For a male to inherit hemophilia the trait only has to be present in the mother, 
while a female would need both the mother and father to have a hemophilia mutation. In 
most cases females who inherit the hemophilia trait will be a carrier, but they will not 
exhibit symptoms. (4) 
Patients with hemophilia can be categorized based upon their severity of disease. 
Approximately 60% of patients with hemophilia are considered to be severe cases having 
less than 1% of normal BCF activity, approximately 15% are moderate cases ranging 
from 1-5%, and approximately 25% are mild cases ranging from 5-40%. (4) Patients with 
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severe hemophilia can experience a bleed (minor or major event) once or twice a week, 
while moderate cases experience a bleed approximately once a month, and mild cases 
bleed only after surgery or trauma.(4) If left untreated hemophilia can cause serious 
damage to joints, muscle tissue, and organ tissue as a result of continuous bleeding and 
swelling. 
Antidepressant medications are prescribed for numerous reasons including but not limited 
to depression, attention-deficit hyperactivity disorder (ADHD), anxiety disorder, and 
bipolar disorder.(5) It is estimated that approximately one in ten adults in the U.S. are 
prescribed an antidepressant medication. (6) Due to the burden of disease, the prevalence 
of depression among patients with hemophilia is approximately 37%. (7)  Selective 
Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors 
(SNRI) are the most commonly prescribed classes of antidepressants prescribed in the 
U.S.; in a study using data from the National Ambulatory Medical Care Survey 
(NAMCS) it was found that 65% of all antidepressant drugs prescribed in 2000 were 
SSRI, while newer SNRI drugs accounted for 17% of the antidepressant utilization. (8) 
Serotonin based antidepressants can affect the body’s ability to clot blood, this may have 
potential negative repercussions for patients with depleted BCF activity. 
 SSRI and SNRI drugs impair platelet aggregation by preventing serotonin reabsorption. 
(9, 10) Serotonin is an important neurotransmitter indirectly involved in platelet 
aggregation. Coated-platelets are rich in collagen, thrombin, and prothrombinase, a serine 
based protein that activates the proteins responsible for procoagulant activity. (11) 
Coated-platelets clot a bleed by adhering to the wall of the blood vessel (von Willebrand 
factor protein produced by the vessel walls), other platelets then crash into the adhered 
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platelets and begin to clump together due to the collagen and thrombin. This webbing 
created by the platelets coated with collagen and thrombin, traps red blood cells as well 
as other proteins in the blood to create a clot. Reducing the level of serotonin available 
will diminish the levels of coated-platelets in the blood. 
We hypothesize that patients who are prescribed SSRI or SNRI medications will be more 
likely to experience a major bleeding event than those not using an SSRI or SNRI 
antidepressant medication. Furthermore, we hypothesize that patients with BCF disorders 
would be prescribed different classes of antidepressant medications as a result of this 
increased risk. The objective of this study is to determine if patients with BCF who are 
prescribed SSRI or SNRI antidepressants are at a higher risk of a major bleeding event 
occurring. A secondary objective of our study is to describe the prescribing frequency of 
antidepressant medication classes for patients with BCF disorders.  
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CHAPTER 2 
REVIEW OF THE LITERATURE 
Although a literature review of studies comparing bleeding rates for patients with BCF 
disorders and the potential impact of antidepressant medication yielded no direct results, 
there was still enough relevant literature available to help provide a basis for this study. 
 
Von Willebrand’s Disease is the most common genetic BCF disorder, found in 0.1-1% of 
the population. Within this patient population it is estimated that 10% of patients display 
symptoms of the disease. (12) Von Willebrand factor (vWF) is an adhesive glycoprotein 
responsible for gluing platelets to the vessel wall to form a clot. James et al. (13) 
identifies some of the major areas of bleeding associated with VWD: mucocutaneous 
(mucosa/skin transition) and epistaxis (nasal) bleeding, as well as easy and frequent 
tissue bruising. (13-15) Female patients frequently experience abnormally heavy bleeding 
during menstruation (menorrhagia). (16) Fressinaud et al. (17) also notes that 
gastrointestinal (GI) bleeding is reported in approximately 10% of VWD patients.  
 
Hemophilia is a genetically transmitted disease on the X-chromosome. Both males and 
females can inherit the disease, but typically only males exhibit symptoms. Females who 
inherit the mutation for hemophilia are considered carriers and are not symptomatic. Plug 
et al (18) conducted an analysis of bleeding in carriers of hemophilia compared to those 
who are non-carriers. The researchers conducted this analysis using self-reported 
information collected from a survey of 546 women within the Netherlands; of these 
women, 274 were carriers of either hemophilia A or B. The researchers found that there 
was a significant increase in bleeding events for patients who were carriers of hemophilia 
 5 
 
when compared to non-carriers. They also reported a statistically significant increase in 
the duration of bleeding for carriers after a tooth extraction, tonsillectomy, or operation. 
Carriers were twice as likely (Relative Risk (RR), 2.3: 95 % Confidence Interval (CI), 1.5 
to 3.4) to have a bleed lasting longer than three hours after one of these procedures when 
compared to non-carriers.  Hemophilia has an estimated incidence of 1 in 5,000 male 
births. (2) Soucie et al. (2) conducted a study for the Center for Disease Control and 
Prevention (CDC) in 1994, estimated that there were approximately 17,000 cases of 
hemophilia (A and B) in the U.S. Using birth and death rates since that time the CDC 
estimates that number has risen to approximately 20,000. (2) Males who inherit the 
hemophilia trait will be symptomatic due to only inheriting the X chromosome from his 
carrier mother and the Y from his father. Males who have hemophilia typically have 
frequent minor bleeds. Major bleeding events are usually the result of surgery or trauma. 
For male patients the majority of bleeding events occur internally and can result in 
serious damage caused to joints, muscle tissue, and organ tissue due to continuous 
bleeding and swelling. (2, 19)  
 
A study conducted by Dawson et al (20) using commercial claims data from 2008-2013 
was used to obtain a baseline measure for the utilization of each antidepressant drug class 
among privately insured patients, irrespective of comorbidity. The study population 
consisted solely of privately insured women age 15-44. The population ranged from 4.6 
million to 6.8 million (per year) during the 5 year duration. They found that 15.4% of 
women had a prescription for an antidepressant filled at least once a year. Antidepressant 
drug claims were categorized by class: SSRI, SNRI, Tricyclic antidepressants (TCA), 
Monoamine oxidase inhibitors (MAOI) and other. It was found that 10.7% of the study 
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population were prescribed a SSRI, 2.8% were prescribed an SNRI, 1.4% were 
prescribed a TCA, 0% were prescribed a MAOI, and 3.9% were prescribed other types. 
They also found that 11.7% of the population filled a prescription for only one class of 
antidepressant, while 3.7% filled prescriptions for multiple classes of antidepressants.  
  
A study by Turner et al. (9, 21, 22) details how SSRI drugs impact the likelihood of a 
bleeding event. The authors explain how SSRIs impact platelet aggregation by preventing 
serotonin from being reabsorbed at a normal rate. The authors concluded that the effect 
on platelets by SSRI drugs may have a clinical importance when considering a patient’s 
risk of bleeding. 
 
Prodan et al. (11) detailed the clinical background of SSRIs and their impact on coated-
platelets. The authors explain that coated-platelets are rich in prothrombinase, a serine 
based protein that activates proteins responsible for procoagulant activity. This study 
found that patients prescribed SSRIs had a statistically significantly lower level of 
coated-platelets in the blood, with an analysis of variance test which yielded a p-value of 
0.046. The study also identified smoking and aspirin use as having a significant impact 
on coated-platelet levels.  
 
It is estimated that approximately one in ten adults in the United States (US) is prescribed 
an antidepressant medication, for a range of indications. (6) It is important to note, due to 
the burden of disease, the prevalence of depression among hemophilia patients is 
estimated at 37%. Iannone et al. (7) identified three covariates that could have a 
significant effect on the rate of depression for patients with hemophilia: unemployment 
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(P=0.01), lack of social support (p=0.04), and occurrences of bleeds per year (P=0.06). 
This study determined that the increase in number of bleeding events per year was 
slightly above the threshold for statistical significance; the study reported a 22% increase 
in the odds of depression for every five bleeding episodes (per year). Barlow et al (23) 
also reported that many hemophilia patients struggle with the physical burden of 
hemophilia, with symptoms including joint bleeds and co-morbidities due to blood 
transfusions. The authors discussed how these comorbidities diminish the patient’s 
quality of life by affecting their education, work, and social activities.   
 
This study will provide patients and physicians more knowledge about the effects of 
SSRI and SNRI antidepressants use for patients with BCF disorders. The aim of this 
study was to determine if patients who are prescribed a SSRI or SNRI medication are 
more likely to experience a major bleeding event then those not using an antidepressant 
medication. The study also determined prescribing frequencies for particular 
antidepressant medications used in patients with BCF disorders.   
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CHAPTER 3 
METHODOLOGY 
Study Population and Design  
This study was conducted as a retrospective cohort study of privately insured U.S. 
citizens who were continuously enrolled throughout 2012. The study population was 
selected from the Optum Clinformatics Data Mart.  Patients were deemed eligible if they 
had continuous enrollment during the entire year of 2012.  The population included 
patients with Hemophilia A and B, Von Willebrand’s Disease, and other non-specified 
blood clotting disorders. BCF disorders are typically diagnosed at an extremely young 
age and persists throughout a patient’s lifetime. We formed our cohort to include all 
patients having any of the International Classification of Diseases (ICD-9) diagnosis 
codes designating a BCF disorder (286.0 - 286.5) available from 2010 to 2012. Most 
antidepressant medications are not FDA approved for children under the age of 12. (6) 
Based upon this information the inclusion criterion for age ranged from 12-100 years old.  
A sample of 621 patients would be required for a cohort study based upon the following 
characteristics: alpha=0.05, power=0.8, incidence=0.3, and a relative risk= 1.25. (24) By 
expanding our study from hemophilia A to all BCF disorders we were able surpass the 
required sample size and yield a study population of 7,998. 
 
Dependent Variable: 
Major bleeding events (hemorrhages) was the dependent variable used for this study. 
Major bleeding events were identified using a series of ICD-9 codes for hemorrhages 
validated in a study by Arnason et al (appendix 4). (25) A patient who had one or more 
documented bleeding event, requiring an inpatient or outpatient visit during a 6 month 
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follow-up period (July 1, 2012 – December 31, 2016) were assigned a designation of 1, 
whereas if no events occurred a designation of 0 was specified. The data source used in 
our study captured only bleeding events that were serious enough to require medical 
attention.  
 
Independent Variables 
SSRI or SNRI antidepressant use was the independent variable of interest. Patients were 
classified as exposed to these medications if they received at least 1 drug claim for either 
an SSRI or SNRI antidepressant during the 3 month period (April 1, 2016 – June 30, 
2016) preceding the 6 month follow-up period for identifying bleeding events. Patients 
without an SSRI or SNRI antidepressant drug claim during this 3 month period were 
categorized as unexposed to these medications. Patients who initiated antidepressant drug 
therapy after this 3 month period were excluded from the analysis. As antidepressant 
polytherapy is common, we excluded users of non-SSRI/SNRI medications from our 
multivariate analyses.  To describe antidepressant medication utilization overall, we 
determined the frequency of use of other antidepressant types including tricyclics, 
MAOIs, serotonin modulators, and miscellaneous antidepressant drugs (Appendix 3). We 
also created an independent variable describing the type of BCF disorder documented. 
BCF types were categorized into four groups: Hemophilia A, Hemophilia B or C, VWD, 
and other clotting factor/ intrinsic anticoagulants. Approximately 6% of the sample 
population had ICD-9 codes for multiple blood clotting disorders; these patients were 
included in the other clotting factor/ intrinsic anticoagulants group.  
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Independent Variables:  
This study also investigated age, gender, geographic region, HIV, HEPC, and diabetes as 
other variables that may impact the risk of a major bleeding event occurring. Values for 
age, gender, and geographic region were determined during the three month baseline 
period. HIV, HEPC, and diabetes status were determined using the available eligibility 
period preceding the follow-up period. Age was tested as a continuous variable and as a 
categorical variable for the predictive model; the categorical version of age was used to 
display the distribution for descriptive statistics. The variable “U.S. state” was used to 
form geographic regions, i.e. Northeast, Midwest, Southeast, Southwest, and West. (26) 
There are numerous indications for which antidepressant drugs can be used.  
 
Statistical analysis: 
The analysis was conducted using the occurrence of at least one major bleeding episode 
as the dependent variable. Descriptive statistics were applied to present the frequency and 
percent of all variables, stratified by exposure and outcome status. Exposure to an SSRI 
or SNRI antidepressant was the primary independent variable of analysis in this study. A 
final logistic regression model was constructed using all variables deemed statistically 
significant. We excluded patients from the multivariate model who were identified as 
users of only other classes of antidepressant drugs (i.e. TCA, MAOI, serotonin 
modulator, or miscellaneous antidepressant). We first created univariate logistic 
regression models for each independent variable, testing each for a statistically significant 
relationship with the study outcome of bleeding events. Univariate models with a P-value 
< 0.20 were considered eligible for inclusion in the initial multivariate model. This 
saturated logistic regression model included the variables age (continuous), gender, 
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region, HIV, HEPC, diabetes, NSAID or anticoagulants, SSRI/ SNRI use, and BCF 
disorder type (hemophilia A, Hemophilia B/C, VWD, and other/ multiple BCF 
disorders). Variables within the model having a P-value<0.05 were considered 
statistically significant for this preliminary model.  
 
To construct a final model we used backwards selection to eliminate variables which 
were included in model selection due to their statistically significant univariate p-values 
(<0.20). Several models were tested against the saturated model for their goodness-of-fit; 
with the intent to simplify a final model, creating the best predictive model possible. The 
likelihood ratio test (LRT) statistic was used to evaluate the different models created. 
Using the LRT statistic we concluded which variables should be included in the final 
model, using the following equation:  
 
     -2(LRT initial model – LRT Complex model)= X -> Zscore -> Chi Sq P-value 
 
Based upon the Chi-Sq distribution and p-value (corresponding to degrees of freedom), 
we decided whether a variable should be included or excluded in the final model. The 
Akaike information criterion (AIC) and Hosmer-Lemeshow test were also applied. A 
smaller AIC value indicated a stronger model fit, while the Hosmer-Lemeshow uses the 
Pearson Chi-Sq statistic to assess model fit. A correlation procedure was performed for 
the 17 variables included in the saturated model. The objective of this correlation analysis 
was to analyze the variables for collinearity effects. A correlation coefficient of 0 would 
represent no correlation between the variables, thus they do not vary together. Variance 
inflation factor (VIF) and tolerance values (TOL) were also analyzed to identify 
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multicollinearity among variables. VIF values greater than 10 would identify variables 
with possible collinearity, while a minimum value for TOL of 0.20 would identify 
variables with multicollinearity effects.(27) Statistically significant variables were tested 
by creating new variable interaction terms, and testing models both with and without the 
new variable. These models were tested against each-other using the -2logL equation:  
 
-2(LRT initial model – LRT Complex model)= X -> Zscore -> Chi Sq P-value 
 
If the Chi-Sq value was statistically significant a variable interaction would be identified.  
 
A relative risk (RR) was calculated to evaluate the effect of the variables included in the 
multivariate logistic regression model with risk of bleeding event, including a 95% 
confidence interval of the point estimate. The RR reflects the increase in risk of bleeding 
associated with a particular variable, and was calculated as the probability of an event 
occurring in the exposed group (event=1) divided by the probability of an event occurring 
in the unexposed group. 
To analyze the prescribing frequency of all types of antidepressants, dispersions of the six 
antidepressant classifications available were identified. Based upon the antidepressant 
classes of interest and univariate analyses we further segmented three of the 
antidepressant classes down to the drug level, SSRI (6 drugs), SNRI (3 drugs), and 
serotonin modulators (3 drugs). (Appendix 2) 
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CHAPTER 4 
Results  
Study population characteristics 
There were 16,124 patients identified as having a blood clotting factor disorder during the 
timeframe. Patients who did not have continuous enrollment through 2012 were excluded 
(N=6855). We then excluded patients under the age of 12 (N=304), and next excluded 
patients having a new a prescription for antidepressant medication occurring after the 3 
month baseline exposure period (N=667). After all exclusions were applied the study 
cohort was reduced to 7,998 patients. We identified 1,531 (19.1%) patients as being 
prescribed an antidepressant medication during the 3 month baseline period. Of these 
1,531 patients, we identified 876 as having an SSRI dispensing, and 377 who had an 
SNRI dispensing.  Using the ICD9 codes for hemorrhage listed in appendix 4, we 
identified major bleeding events that occurred between 6/1/12 to 12/31/12. A total of 238 
patients had at least one major bleeding event, among the 7,998 patients in the study 
population (3.476%). Of these 238 patients who had a major bleeding event, 42 (3.4%) 
were prescribed either an SSRI or SNRI antidepressant medication, while 196 (2.9%) 
were not.   
The study population’s predominant characteristics were 65.15% female, 40.67% of 
patients were between 46-65 years old, 30% lived in the southeast, 0.79% of patients had 
a diagnosis for HIV, 1.68% of patients had a diagnosis of HEPC, 13.43% of patients had 
a diagnosis of diabetes, 20.63% were prescribed a NSAID, 12.59% were prescribed an 
anticoagulant, 16.90% were prescribed an SSRI or SNRI, while 22.73% were prescribed 
an antidepressant of any kind. The prevalence of major bleeding events within the study 
population was 2.98%.  
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The bivariate analyses identified several variables that were associated with major 
bleeding events: older age (p=0.0001), male gender (p=0.0001), diabetes (p=0.0001), 
NSAID use (p=0.0004), anticoagulant use (p=0.0004), Hemophilia A (p=0.0004), and 
VWD (p=0.0006).  
Antidepressant drug utilization in this patient population was similar to that of the general 
population. We found that 876 (57.2%) patients were prescribed an SSRI, 377 (24.6%) 
patients were prescribed an SNRI, 150 (9.8%) patients were prescribed a TCA, less than 
10 were prescribed an MAOI antidepressant, 171 (11.2%) received a serotonin 
modulator, and 254 (16.6%) patients were prescribed an antidepressant classified as 
miscellaneous. During the 3 month baseline period 1,265 patients received only one class 
of antidepressant, 236 patients received 2 different classes of antidepressants, and 31 
patients received 3 classes of antidepressant drugs.  
The use of SSRI or SNRI antidepressants was more frequent among older patients, 
females, and patients with diabetes (p < 0.0001 for all comparisons). Users of NSAIDs 
and oral anticoagulants were also more likely to be prescribed SSRI or SNRI 
antidepressants as compared with patients not receiving NSAIDs or oral anticoagulants (p 
< 0.0001). Further detail is presented in Table 1c.  
 
Univariate Logistic Regression Models 
In univariate logistic regression analyses we identified variables having a statistically 
significant association with the occurrence of a major bleeding event (Table 3). In the 
univariate analysis, there was no significant increase in the occurrence of a bleeding 
event among patients prescribed an SSRI or SNRI medication (P=0.68, RR=1.09, 95% 
CI= 0.74 – 1.60). Univariate analyses were also conducted for age, gender, region, HIV, 
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HEPC, diabetes, and drugs known to affect bleeding. Age was tested as both a continuous 
variable and a categorical variable, and both versions had a statistically significant effect 
on the risk of bleeding (p=<0.0001). When analyzing age in categories there was a 
noticeable increase in risk with advancing age. Using 26 to 45 years old as the reference 
group, there was no difference in risk when compared to the age group 12 to 25 years old. 
When comparing patients between the ages of 46-65 years to patients age 26-45 years of 
age, the RR was 1.75 (CI: 1.23-2.51). For patients between 66 and 91 years of age 
(reference 26-45 years), the risk of major bleeding was more than 3 times higher (RR 
3.40; 95% CI: 2.27-5.08). A univariate model for patient gender was also tested using 
female gender as the reference category. This model had a p=value of <0.0001 and a RR 
of 1.83 (95% CI: 1.40-2.40). Based upon this information we can conclude that male 
patients were at a significantly higher risk of having a major bleeding event as compared 
with female patients. U.S. regions were also evaluated, but no statistically significant 
effect was found between different geographic areas. Comorbidities of interest at the 
beginning of this study were identified as HIV, HEPC, and diabetes. Due to contaminated 
blood in the 1970’s and 1980’s many patients who required numerous blood transfusions 
over time contracted HIV and HEPC. (28, 29) This study found no significant increase in 
the risk of major bleeding events for patients with either disease. The RR for HIV was 
1.80 (95% CI: 0.56-5.80) with a p-value=0.3245, and the relative risk for HEPC was 2.05 
(95% CI: 0.94-4.45; p=0.0695). (Table 3)  A univariate analysis assessing the influence 
of diabetes revealed that patients with this disease were at an increased risk of a major 
bleeding event occurring (RR 1.78; 95% CI: 1.27-2.49; p=0.0007). Lastly, a univariate 
analysis was conducted analyzing drug classes that are known to increase the risk of 
bleeding. Users of NSAIDs were 54% more likely to experience a bleeding event (RR 
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1.54; 95% CI: 1.14-2.08), while users of anticoagulants were twice as likely to 
experience a bleeding event (RR 2.00; 95% CI: 1.43-2.78).  
 
Univariate analyses were also conducted to assess bleeding risk according to type of BCF 
disorder. We found that patients with Hemophilia A had a RR of 2.03 (95% CI: 1.52-
2.72, p=0.0001); patients with Hemophilia B/C had a non-significant RR of 0.93 (95% 
CI: 0.59-1.47, p= 0.7661), patients with VWD had a non-significant RR of 0.75 (95% CI: 
CI: 0.54-1.03, p=0.0737), and those with other/multiple clotting factors had a RR of 1.12 
(95% CI: 0.86-1.03, p= 0.4088).  Based upon these findings we conclude that older age, 
male gender, diabetes, NSAID use, anticoagulant use, and the presence of HEP-C, 
Hemophilia A, and VWD met the selection criteria for advancing to the multivariate 
model analysis.  
 
Multivariate Logistic Regression Modeling 
Two multivariate logistic regression models were constructed, a saturated model and a 
reduced model which includes statistically significant variables or strata. The saturated 
model (Table 4) included the variables age, gender, region, HIV, HEPC, diabetes, SSRI 
or SNRI use, NSAID use, anticoagulant use, Hemophilia A, Hemophilia B/C, VWD, and 
other/ multiple BCF disorders. Several variables were statistically significant in this 
model: age, gender, NSAID use, anticoagulant use, and Hemophilia A (p <0.05 for all). 
Within this model VWD was just above significance (p – 0.074). Next, a reduced model 
was constructed using the variables determined to be statistically significant from the 
univariate analyses. This reduced model included nine variables: age, gender, diabetes, 
Hemophilia A, VWD, NSAID use, HEP-C, SSRI or SNRI use, and anticoagulant use. 
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Based upon this model a final model was constructed eliminating non-significant 
variables using backwards elimination. The final model included age, gender, NSAID 
use, anticoagulant use, hemophilia A, VWD, and SSRI or SNRI use, as risk factors for 
the occurrence of a major bleeding event. Based upon this final model we can conclude 
that the risk of a major bleeding event was higher for males, the older population, those 
patients prescribed NSAID or anticoagulant medications, and patients who had 
Hemophilia A or VWD.   
 
Discussion 
 
BCF disorders are complex diseases to live with; patients must deal with sporadic 
bleeding under normal conditions. Serotonin-based antidepressant medications lower 
levels of serotonin in the blood, a necessary component in blood coagulation. Any 
association between serotonin-based antidepressants and bleeding events would be a 
relevant concern for BCF disorder patients and their physicians.   
 
The results of our analyses revealed that age, gender, NSAID use, anticoagulant use, and 
Hemophilia A were risk factors in major bleeding. This information coincides with the 
results of other research available. Studies have revealed that as patients get older they 
are at a significantly higher risk of bleeding events. (30-32) The risk of major bleeding 
events due to NSAID use likely varies by patient as well as the duration of on NSAID 
therapy. A 16 week study found that there was no increased risk of bleeding events for a 
hemophilic taking 1600 mg of ibuprofen daily. (30) A study assessing upper 
gastrointestinal bleeding in hemophiliacs found that patients taking an NSAID (naproxen, 
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ibuprofen, or diclofenac) for less than one month were at a statistically significant 
increased risk of GI bleeding. They also reported that patients with prolonged NSAID use 
(>1 month) were not at an increased risk of bleeding. The researchers further reported 
that Cox-2-inhibitors (Rofecoxib and Celecoxib) are a safer alternative to NSAIDs for 
hemophiliac patients. (31)  There is little information known about the risk of bleeding in 
BCF patients taking anticoagulants. Our study results correspond to the known risks of 
anticoagulants in the general population. (33)  Additionally, we tested two-way variable 
interactions but did not identify any interaction effects between the variables included in 
our study.  
 
We did not identify an association between SSRI or SNRI use and major bleeding events 
in our study; although other studies have shown that there is a moderate increase in 
particular types of bleeding among patients using these drugs. Castro et al. (34) found 
that patients who used antidepressant medications that have a high affinity for serotonin 
transporters had an increase in the likelihood of gastrointestinal bleeding. A meta-
analysis conducted by Hackam et al. (35) found an association between SSRI use and 
intracranial hemorrhages (adjusted RR: 1.51; 95% CI: 1.26-1.81). Their analysis also 
found an association between SSRI use and intracerebral hemorrhages (adjusted RR: 
1.68; 95% CI: 1.46-1.91), and an increase in risk in patients who were taking both SSRIs 
and anticoagulants (RR 1.61; 95% CI: 1.04-2.51).  
 
Strengths and Limitations: 
Due in part to the rarity of hemophilia and other bleeding disorders, there exists little 
information published about antidepressant use in the hemophilia population. This study 
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provides only a preliminary investigation of the risk associated with antidepressant use 
among patients with BCF disorders using a retrospective cohort design. Further study 
examining particular SSRI and SNRI medication products and hemorrhage types may 
reveal increases in bleeding risk that were not evident in our aggregate analyses. Our 
analysis highlighted age, gender, and NSAID/ anticoagulant use as key risk factors for 
the occurrence of bleeding events. This study also provides descriptive statistics detailing 
the antidepressant medication classes used among this sample of patients having a BCF 
disorder, finding that SSRI and SNRI medications were commonly prescribed.  
 
There were limitations of this study to be noted. The primary limitation of this study 
relates to data source, which was collected by a national health insurance company, and is 
based upon individual patient healthcare claims. We were only able to capture episodes 
of bleeding that that were serious enough to require medical care. Other limitations of 
claims data include a lack of detail about the event (intensity and outcomes), lack of 
patient history and demographics, and pharmacy claims do not indicate if the patient 
actually ingested the drug. Claims data also lack information about the patient’s severity 
of disease and bleeding treatment course (prophylactic or acute treatment).  
 
The sample sizes for users of the antidepressant medications fluvoxamine, olanzapine/ 
fluoxetine, venlafaxine, and nefazodone were all less than or equal to 10 total patients. In 
these instances it was possible that no bleeding events occurred because the sample size 
was so small. Another limitation to this study is the inability to identify major bleeding 
events as being related to antidepressant use, and not as a result of some other factor. We 
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may have also failed to identify patients having diseases such as diabetes, HIV and HEPC 
if no recent claim associated with these conditions was submitted.  
 
Bleeding events were recorded as either the patient had at least one bleeding event 
requiring medical attention, or they did not. We did not ascertain the frequency of 
bleeding events per patient.  We were also unable to identify bleeding events due to 
trauma or illness.  Lastly, the generalizability of this study population may not extend to 
all patients with BCF disorders beyond the commercially insured. These results should 
not be generalized to programs such as Medicaid or Medicare.  
 
Further research using data collected at hemophilia treatment centers or questionnaires 
from patients may be able to capture less severe bleeding events. It would also be worth 
investigating the association between antidepressant use and the duration of bleeding 
events. Being able to expand the type and number of bleeding events that occur may add 
further insight into a potential association between antidepressant use and bleeding events 
in the BCF disorder population.  
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CHAPTER 5 
 
CONCLUSION 
 
Serotonin based antidepressant medications are known to alter the serotonin levels within 
the blood. Altering serotonin levels reduce the concentration of coated-platelets within 
the blood responsible for blood clotting. There is little known information on the 
association between antidepressant use and episodes of major bleeding in patients with 
blood clotting factor disorders.  
 
This study did not identify an association between the use SSRI or SNRI antidepressant 
medications and an increase in the occurrence of major bleeding events. Other important 
risk factors for major bleeding that were identified in our study included advancing 
patient age, male gender, and the use of NSAIDs and oral anticoagulants.  
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APPENDIX 1: TABLES 
Table 1a: Demographic and Clinical Characteristics of Patients with Blood Clotting 
Factor Disorders and Association with the Occurrence of a Bleeding Event (N=7,998) 
 No Bleeding Event  
At least 1 
Bleeding 
Event  
Chi-Sq 
P-Value 
Cohort 
Population 
7760 (97%) 238 (3%)  
 Age    <0.0001 
12-25 Years old 1,116 (98.20%) 20 (1.80%)  
26-45 Years old 2,563 (98.16%) 48 (1.84%)  
46-65 Years old 3,144 (96.64%) 109 (3.35%)  
66-91 Years old 937 (93.89%) 61 (6.11%)  
Gender   <0.0001 
Female 5090 (97.68%) 121 (2.32%)  
Male  2670 (95.80%) 117 (4.20%)  
Region   0.9390 
Northeast 1,288 (97.21%) 37 (2.79%)  
Southeast 2,322 (96.79%) 77 (3.21%)  
Midwest 2,039 (97.10%) 61 (2.90%)  
West  1,083 (97.22%) 31 (2.78%)  
Southwest 1,027 (96.98%) 32 (3.02%)  
HIV   0.4367 
Yes 60  < 5   
HEPC   0.1225 
Yes 127 (94.78%) 7 (5.22%)  
Diabetes    0.0001 
Yes 1,022 (95.16%) 52 (4.84%)  
NSAID Use   0.0004 
Yes 1,579 (95.70%) 71 (4.30%)  
Anticoagulant Use   0.0004 
Yes 959 (95.23%) 48 (4.77%)  
SSRI   0.8440 
Yes 849 (96.92%) 27 (3.08%)  
SNRI   0.0726 
Yes 360 (95.49%) 17 (4.51%)  
 
 
 
 
 
 23 
 
 
Table 1b: Occurrence of a Bleeding Event by Type of Blood Clotting Factor Disorder 
(N=7,998) 
 
 No Event Bleeding Event  P-value 
Hemophilia A   0.0004 
Yes 966 (95.64%) 44 (4.36%)  
Hemophilia B/ C   0.7668 
Yes 587 (97.02%) 18 (2.98%)  
VWD   0.0006 
Yes 1,786 (98.13%) 34 (1.87%)  
Other Clotting Factors/ 
Intrinsic Anticoagulants   
0.4088 
Yes 4,421 (96.89%) 142 (3.11%)  
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Table 1c: Exposure to SSRI or SNRI Antidepressants by Patient Characteristic (N=7,998)  
 
 
No Exposure to 
SSRI  or SNRI 
Exposure to 
SSRI or SNRI  
P-Value 
Cohort Population    
 Age    <0.0001 
12-25 Years old 1,050 (92.40%) 86 (7.60%)  
26-45 Years old 2,239 (85.75%) 372 (14.25%)  
46-65 Years old 2,658 (81.71%) 595 (18.29%)  
66-91 Years old 813 (82.87%) 168 (17.13%)  
Gender   <0.0001 
Female 4,246 (81.48%) 965 (18.52%)  
Male  2,527 (90.67%) 260 (9.33%)  
Region   0.4986 
Northeast 1,161 (87.62%) 164 (12.38%)  
Southeast 2,002 (83.41%) 398 (16.59%)  
Midwest 1,755 (83.57%) 345 (16.43%)  
West  953 (85.55%) 161 (14.45%)  
Southwest 902 (85.17%) 157 (14.83%)  
HIV   0.0567 
Yes 59  >5  
HEP-C   0.9002 
Yes 114 (85.07%) 20 (14.93%)  
Diabetes    <0.0001 
Yes 852 (79.33%) 222 (20.67%)  
NSAID Use   <0.0001 
Yes 1,333 (80.79%) 317 (19.21%)  
Anticoagulant Use   <0.0001 
Yes 782 (77.66%) 225(22.34%)  
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Table 2a: Frequency of Antidepressant Use by Drug Class (n=1,531) 
 
Antidepressant Class Number of Patients (%) 
SSRI 876 (57.2%) 
SNRI 377 (24.6%) 
TCA 150 (9.8%) 
MAOI < 5  
Serotonin Modulator 171 (11.2%) 
Miscellaneous 254 (16.6%) 
* Patients can be represented in multiple classes due to combination therapy  
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Table 2b: Frequency of a Bleeding Event by Antidepressant Medication Type (N=1,531)  
 
Drug  
Patients experiencing a 
bleeding event n (%)  
SSRI  
Citalopram  
Yes 253 (16.5%) 
Escitalopram  
Yes 166 (10.8%) 
fluoxetine  
Yes 154 (10.0%) 
Fluvoxamine  
Yes 6 (0.4%)  
Paroxetine  
Yes 63 (4.1%) 
Sertraline  
Yes 261 (17.0%) 
SNRI  
Duloxetine  
Yes 176 (11.5%) 
Desvenlafaxine  
Yes 48 (3.1%) 
Venlafaxine  
Yes 156 (10.2%) 
Modulators  
Nefazodone  
Yes < 5   
Trazodone  
Yes 156 (10.2%) 
Vilazodone  
Yes 15 (1.0%) 
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Table 3: Univariate Logistic Regression Analyses: Risk of Bleeding Events in Patients 
with Blood Factor Clotting Disorders; Risk According to Demographics, Clinical 
Characteristics and Antidepressant Use 
 
Univariate models OR (95% CI) P-Value 
age (continuous) 1.02 (1.01-1.03) <0.0001 
   
Age (categorical)  <0.0001 
  12-25 years old 0.88 (0.50-1.53))  
  26-45 years old (ref) 1.00  
  46-65 years old 1.75 (1.23-2.51)  
  66-91 years old 3.40 (2.27-5.08)  
   
Gender  <0.0001 
  Female (ref) 1.00  
  Male 1.83 (1.40-2.40)  
   
Region  0.86 
  Northeast 1.00  
  Midwest 0.95 (0.62-1.46)  
  Southeast 1.14 (0.76-1.71)  
  Southwest 1.05 (0.64-1.73)  
  West 0.95 (0.58-1.56)  
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Table 3 continued: Univariate Logistic Regression Analyses: Risk of Bleeding Events in 
Patients with Blood Factor Clotting Disorders; Risk According to Demographics, Clinical 
Characteristics and Antidepressant Use 
 
Comorbidities OR (95% CI) P-Value 
HIV  0.3245 
  no  (ref) 1.00  
  yes 1.80 (0.56-5.80)  
   
HEPC  0.0695 
  no  (ref) 1.00  
  yes 2.05 (0.94-4.45)  
   
Diabetes  0.0007 
  no  (ref) 1.00  
  yes 1.78 (1.27-2.49)  
   
NSAID Use  0.0051 
  no  (ref) 1.00  
  Yes 1.54 (1.14-2.08)  
   
Anticoagulant Use  <0.0001 
  no  (ref) 1.00  
  yes 2.00 (1.43-2.78)  
 
Antidepressant Class 
OR (95% CI) 
P-Value 
SSRI or SNRI  0.6795 
  no  (ref) 1.00  
  yes 1.09 (0.74-1.60)  
   
Hemophilia A  <0.0001 
Yes 2.03 (1.52-2.72)  
   
Hemophilia B/ C  0.7661 
Yes 0.93 (0.59-1.47)  
   
VWD  0.0737 
Yes 0.75 (0.54-1.03)  
   
Other Clotting Factors/ 
Intrinsic Anticoagulants 
 
0.4088 
Yes 1.12 (0.86-1.45)  
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Table 4: Risk of Bleeding Events According to Demographic, Clinical Characteristics, 
and Antidepressant Medication Use: Saturated Logistic Regression Model  
 
Variable   
 OR (95% CI) P-Value 
Age 1.02 (1.01-1.03) <0.0001 
Gender  0.0052 
Female 1.00 Ref 
Male 1.51 (1.13-2.00) 0.0052 
Region  0.9178 
Northeast 1.00 Ref 
Midwest 0.93 (0.61-1.42) 0.5867 
Southeast 1.03 (0.69-1.54)  0.9146 
Southwest 0.99 (0.61-1.62) 0.9881 
West 0.90 (0.55-1.47) 0.5981 
HIV 1.19 (0.36-3.93) 0.9534 
Diabetes 1.32 (0.95-1.84) 0.2599 
Hepatitis C 1.63 (0.73-3.61) 0.6878 
NSAID Use 1.56 (1.14-2.13) 0.0065 
Anticoagulant Use 1.98 (1.40-2.80) <0.0001 
SSRI or SNRI 1.00 (0.67-1.50) 0.9898 
Hemophilia A 2.37 (1.64-3.42) <0.0001 
Hemophilia B/ C 1.15 (0.70-1.92) 0.5770 
VWD 1.49 (0.98-2.26) 0.0625 
Other Clotting Factors/ 
Intrinsic Anticoagulants 1.29 (0.90-1.85) 0.1610 
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Table 5: Risk of Bleeding Events According to Demographic, Clinical Characteristics, 
and Antidepressant Medication Use: Fitted Multivariate Logistic Regression Model  
 
Multivariate models  OR (95% CI) P-Value 
Age 1.02 (1.02-1.03) <0.0001 
Male gender 1.53 (1.15-2.02) 0.0031 
NSAID Use 1.66 (1.18-2.35) 0.0039 
Anticoagulant Use 2.22 (1.55-3.17) <0.0001 
Hemophilia A 2.12 (1.54-2.93) <0.0001 
VWD 1.27 (0.88-1.84) 0.2010 
SSRI or SNRI Use 1.02 (0.68-1.1) 0.9325 
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APPENDIX 2: Flow Charts 
Figure 1: Study Sample Selection Flow Chart 
 
 
SSRI: Selective Serotonin Reuptake Inhibitor 
SNRI: Serotonin Norepinephrine Reuptake Inhibitor 
 
  
Medical Cohort Antidepressant Cohort
Initial Study Population: 
16,124 Patients 
Continuously enrolled 
from 1/1/12 to 12/31/12:
9269 Patients
Age >12: 8,665 Patients
Patients with a prescription drug claim for a 
SSRI, SNRI, Tricyclic, monoamine, serotonin 
modulator, and miscelaneous:
2,952 Patients
Patients with antidepressant drug claims 
submitted from 3/1/12 to 6/1/12, and had 
existing medical records:
1,994 Patients
Those whose first prescription 
drug claim occurred 6/1/12 were 
EXCLUDED:
667 Patients
Those on SNRIs:
377 Patients 
Those of SSRIs: 
876 Patients 
Antidepressant
Exposure: 
1,531 Patients
Cohort: 7,998 Patients
 32 
 
Figure 2: Frequency of Utilization of Antidepressant Medications 
 
 
 
 
 
 
 
 
 
 
 
 
All Antidepressant 
Exposures: 
1,531 Patients
SNRI:
377 (24.6%)
Tricyclics:
150 (9.8%) 
SSRI:
876 (57.2%) 
miscellaneous:
254 (16.6%) 
Modulators:
171 (11.2%) 
Monoamines:
< 5 Patients 
Note: some patients were prescribed 
multiple antidepressant classes or 
drugs during the index period.
Citalopram:
253 (16.5%) 
Patients
Escitalopram:
166 (10.8%) 
Patients
Fluoxetine:
152 (10.0%) 
Patients
Fluvoxamine:
6 (0.4%) Patients
Duloxetine:
176 (11.5%) 
Patients
Desvenlafaxine:
48 (3.1%) 
Patients
Venlafaxine:
153 (10.1%) 
Patients
Paroxetine:
63 (4.1%) 
Patients
Nefazodone:
< 5 patients 
Vilazodone:
15 (1.0%) 
Patients
Trazadone:
156 (10.2%) 
Patients
Sertraline:
261 (17.0%) 
Patients
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APPENDIX 3: Diagnosis codes for blood clotting disorders, hemorrhages, and drug class 
codes 
 
Blood Clotting Factor Disorders ICD-9 Code 
Congenital factor VIII disorder (hemophilia A) 286.0 
Congenital factor IX disorder (Hemophilia B) 286.1 
Congenital factor XI deficiency (Hemophilia C) 286.2 
Congenital deficiency of other clotting factors 286.3 
Von Willebrand's disease 286.4 
Hemorrhagic disorder due to intrinsic circulating anticoagulants 286.5 
 
Antidepressant drug classifications Optum code 
Selective Serotonin Reuptake Inhibitor 28160420 
Serotonin Norepinephrine Reuptake Inhibitor 28160416 
Tricyclics 28160428 
Monoamine Oxidase Inhibitors 28160412 
Antidepressants, Miscellaneous 28160492 
Serotonin Modulators 28160424 
 
Other drugs  Code 
Anticoagulants, Miscellaneous 20120492 
Heparins 20120416 
Direct Factor Xa Inhibitors 20120414 
Direct Thrombin inhibitors 20120412 
Coumarin Derivatives  20120408 
Cyclooxygenase=2 (COx-2) Inhibitors 28080408 
Salicylates 28080424 
Other NSAIDs Agents 28080492 
 
Comorbidities ICD-9 Codes 
HIV V08 
AIDS 042 
HIV-2 07953 
Human T-cell lymphotrophic virus, type 1 (HTLV-I) 07951 
HIV counseling v6544 
Acute Hepatitis C with Hepatic Coma 07041 
Chronic Hepatitis C With Hepatic Coma 07044 
Chronic Hepatitis C without Hepatic Coma 07054 
Unspecified Viral Hepatitis C without Hepatic Coma 07070 
Unspecified Viral Hepatitis C with Hepatic Coma 07071 
Diabetes Mellitus w/o mention of complications, Type II, controlled 25000 
Diabetes Mellitus w/o mention of complications, Type I, controlled 25001 
Diabetes Mellitus w/o mention of complications, Type II, uncontrolled 25002 
Diabetes Mellitus w/o mention of complications, Type I, uncontrolled 25003 
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APPENDIX 4: Identifying bleeding events using ICD-9 codes for Hemorrhages (25) 
 
description Code 
hemopericardium 423 
subarachnoid hemorrhage 430 
intracerebral hemorrhage 431 
Nontraum extradural hem 432 
Subdural hemorrhage 432.1 
Intracranial hemorr NOS 432.9 
int hemrrhoid w comp nec 455.2 
ext hemrrhoid w comp nec 455.5 
hemrrhoid NOS w comp nec 455.8 
hemorrhage NOS 459 
esophag varices w bleed 456 
esoph varices in oth dis 456.2 
mallory–weiss syndrome 530.7 
esophageal disorder nec 530.8 
ac stomach ulcer w hem 531 
ac stomach ulcer w hem-obst 531.01 
ac stomach ulc w hem/perf 531.2 
ac stomach ulc w hem/perf-obst 531.21 
chr stomach ulc w hem 531.4 
chr stomach ulc w hem-obst 531.41 
chr stomach ulc hem/perf 531.6 
chr stomach ulc hem/perf-obst 531.61 
ac duodenal ulcer w hem 532 
ac duodenal ulcer w hem-obst 532.01 
ac duodenal ulc w hem/perf 532.2 
ac duodenal ulc w hem/perf-obst 532.21 
chr duoden ulcer w hem 532.4 
chr duoden ulcer w hem-obst 532.41 
chr duoden ulc w hem/perf 532.6 
chr duoden ulc w hem/perf-obst 532.61 
ac peptic ulc w hemorr 533 
ac peptic ulc w hemorr-obst 533.01 
ac peptic ulc w hem/perf 533.2 
ac peptic ulc w hem/perf-obst 533.21 
chr peptic ulcer w hem 533.4 
chr peptic ulcer w hem-obst 533.41 
chr peptic lc w hem/perf 533.6 
chr peptic lc w hem/perf-obst 533.61 
ac marginal ulcer w hem 534 
ac marginal ulcer w hem-obst 534.01 
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ac margin ulc w hem/perf 534.2 
ac margin ulc w hem/perf-obst 534.21 
chr marginal ulcer w hem 534.4 
chr marginal ulcer w hem-obst 534.41 
chr marg ulc w hem/perf 534.6 
chr marg ulc w hem/perf-obst 534.61 
acute gastritis with hemorrhage 535.01 
Atrophic gastritis with hemorrhage 535.11 
gastr mucosoal hypertroph with 
hemorrhage 535.21 
alcoholic gastritis with hemorrhage 535.31 
gastritis nec with hemorrhage 535.41 
gastritis/duodenitis NOS with hemorrhage 535.51 
duodenitis with hemorrhage 535.61 
gastroduodenal dis nec 537.8 
diverticula sm intestine w hemorrhage 562.02 
diverticulitis sm intestine w hemorrhage 562.03 
diverticula of colon w hemorrhage 562.12 
diverticulitis of colon w hemorrhage 562.13 
hemoperitoneum 568.81 
rectal and anal hemorrhage 569.3 
angiodysplasia with hem nec 569.85 
hematemesis 578 
blood in stool 578.1 
Gastrointest hemorr NOS 578.9 
renalvascular disorder 593.81 
hematuria 599.7 
noninflam dis vagina nec 623.8 
excessive menstruation 626.2 
metrorrhagia 626.6 
hemarthrosis (nonspecific) 719.1 
hemarthrosis (shoulder) 719.11 
hemarthrosis (upper arm) 719.12 
hemarthrosis (forearm) 719.13 
hemarthrosis (hand) 719.14 
hemarthrosis (pelvis) 719.15 
hemarthrosis (leg) 719.16 
hemarthrosis (ankle) 719.17 
hemarthrosis (joint, neck) 719.18 
epistaxis 784.7 
Hemorrhage from throat 784.8 
hemoptysis 786.3 
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APPENDIX 5: IRB exempt approval 
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